Scholarly Research Suggests Xarelto Lawsuit Plaintiffs’ Claims Are Credible

July 02, 2016 – – TheProductLawyers.com reports on additional support from the academic community for the cases against Xarelto and its manufacturers—Bayer AG and Janssen Pharmaceuticals. Several studies published in the last year may indicate plausible links between plaintiff allegations of the elevated risk of severe bleeding events and use of the anticoagulant, Xarelto.

One study, published in the April of 2015 issue of the British Medical Journal (BMJ), proposes a substantive link to a doubled risk of gastrointestinal bleeding for patients who switched to Xarelto after using warfarin. The researchers screened almost 46,000 complete medical histories of patients who used warfarin as part of an anticoagulant regimen but switched to Xarelto after its 2011 market debut.

Another study published in JAMA Ophthalmology in June of 2015 indicates a similar connection. Drs. Judy Hun and John C. Hwang observed patients in their joint practice who ranged in age from 70 to 89. Many patients had an extended history of use of the anticoagulant warfarin but had elected to switch to Xarelto after the FDA rendered its approval. All patients were currently taking the new-generation anticoagulant.

While they noted that there was an elevated risk for vitreous hemorrhages in many patients, overall, the doctors observed, “In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated.” This indicates an especially heightened risk among patients who switched drugs, rather than those who had taken no other anticoagulants prior.

This data lends credibility to the allegations of more than 2,800 plaintiffs against Xarelto and the drug’s manufacturers. Late in 2015, the large number of cases with claims in common were combined to form the multidistrict litigation (MDL) No. 2592. This will expedite the legal proceedings. Judge Eldon Fallon has been appointed to preside over the proceedings in the Eastern District of Louisiana when the MDL cases appear in court in the near future. Until such time, all subsequent individual suits brought against the drug and its manufacturers will be combined with MDL 2592.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011138